XSTO
SYNACT
Market cap95mUSD
Jun 05, Last price
18.72SEK
1D
0.11%
1Q
9.54%
Jan 2017
236.27%
IPO
271.50%
Name
SynAct Pharma AB
Chart & Performance
Profile
SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 89,804 | 139,759 | 106,742 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (89,804) | (139,759) | (106,742) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 8,424 | (8,466) | (7,860) | |||||||
Tax Rate | ||||||||||
NOPAT | (98,228) | (131,293) | (98,882) | |||||||
Net income | (82,401) -61.82% | (215,810) 117.54% | (99,205) 43.14% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 59,459 | 228,945 | ||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 595 | 579 | 1,000 | |||||||
Long-term debt | 3,167 | 695 | 3,128 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 8,304 | 8,820 | (1,000) | |||||||
Net debt | (57,447) | (61,167) | (104,207) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (89,197) | (100,177) | (117,555) | |||||||
CAPEX | ||||||||||
Cash from investing activities | 370 | 27 | ||||||||
Cash from financing activities | 87,405 | 53,984 | 200,712 | |||||||
FCF | (104,434) | (111,885) | (115,771) | |||||||
Balance | ||||||||||
Cash | 61,209 | 62,395 | 108,245 | |||||||
Long term investments | 46 | 90 | ||||||||
Excess cash | 61,209 | 62,441 | 108,335 | |||||||
Stockholders' equity | (567,191) | (470,386) | (268,319) | |||||||
Invested Capital | 791,544 | 656,029 | 395,353 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 39,533 | 32,524 | 27,585 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | (89,804) | (64,423) | (105,724) | |||||||
EV/EBITDA | ||||||||||
Interest | 294 | |||||||||
Interest/NOPBT |